We chart course for the uncharted — a holding company stewarding ventures that push the boundary of science, commerce, and possibility. Our flag flies over enterprises built to outlast the storm.
We acquire and incubate with the patience of an estate, not the urgency of a portfolio. Our companies are built to last decades, not quarters.
We invest where rigor meets ambition. Peptide therapeutics, biological engineering, and the next century of human performance.
Our subsidiaries operate with autonomy. We provide the ship, the maps, and the wind — they choose the destination and command the deck.
Pirate Ship Fielder holds a single, focused fleet — companies operating at the frontier of peptide therapeutics. Each is built for depth, not breadth.
Retara is our wholly-owned subsidiary specializing in next-generation peptide therapeutics, with particular focus on retatrutide and its emerging applications.
Retara is a specialized peptide research and supply company, focused on the development, sourcing, and distribution of premium peptides — with retatrutide as our cornerstone molecule. We serve researchers and clinical partners with uncompromising purity and provenance.
We do not raise the flag of common sails. We field the ships that others cannot — and steer them toward shores not yet on any map.
Pirate Ship Fielder is a private holding company. For commercial inquiries regarding our subsidiary Retara and its peptide programs, please visit sales.retara.org. For all corporate matters, reach us directly below.